Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cell Medica Announces Senior Management Appointments

Published: Friday, March 08, 2013
Last Updated: Thursday, March 07, 2013
Bookmark and Share
Key appointments to Cell Medica's senior executive team.

Cell Medica has announced key appointments to its senior executive team.

The strengthened management team will enable Cell Medica to broaden its product development activities, particularly in the US, and will support further international growth.

Dr. Kurt Gunter joins Cell Medica as Chief Medical Officer and will have a senior role in managing the clinical and regulatory aspects of the Company’s therapeutic products with a focus on the cancer immunotherapy program.

As Chief Financial Officer, Jeff Hammel will be responsible for Cell Medica’s global financial and business management systems to drive the continued growth of Cell Medica’s commercial operations in both Europe and the US.

Ross Durland, PhD, has joined as Senior Vice President Development with global responsibility for product development activities.

Ross will focus on the Company’s pipeline strategy while also assisting in setting up the manufacturing operations in the US.

The new members of the executive team will be based in Cell Medica’s recently established US office in Houston, Texas and will have global responsibility for their respective functions.

Also joining the Houston office are Cynthia Molina, Senior Director Regulatory Affairs and Shannon Inman, Director Clinical Operations, each with regional responsibility for the US.

Gregg Sando, CEO of Cell Medica, commented, “Expanding our management team with such experienced biotech professionals is a crucial step as we extend our operations to the US market. For Cell Medica, this represents an important growth milestone in our strategy to build an industry leader in cellular therapeutics on a global basis.”

Dr. Kurt Gunter, Chief Medical Officer
Kurt has devoted his career to the development of cell and gene therapies and brings significant commercial experience to Cell Medica from his previous positions at Hospira, ViaCell and Transkaryotic Therapies.

As current President of the International Society for Cellular Therapy (ISCT), Kurt plays a worldwide leadership role in promoting the understanding of the clinical, regulatory, manufacturing and marketing requirements for the successful development of cell and gene therapies.

Prior to his biotech career, he worked at the U.S. Food and Drug Administration as a Medical Officer and was appointed Acting Deputy Director of the Division of Cell and Gene Therapy within the Center for Biologics Evaluation and Research (CBER).

Jeff Hammel, Chief Financial Officer
Jeff joins Cell Medica with over 17 years of broad financial and operational experience in the healthcare industry. In his previous role as Chief Financial Officer for the largest operating division of Orthofix International NV, Jeff managed the global financial operations for a medical technology business with $300 million revenues across all major international markets.

Jeff played an active role in providing financial and analytical support to manage strategic and operational goals. He was also a key member of the integration team for a significant acquisition.

Prior to Orthofix, Jeff spent eight years at the head office of Eli Lilly & Company where his final position was US Controller for the $7.0 billion US pharmaceutical division.

Ross Durland, Senior Vice President Development
Ross has over 20 years of experience in the development of highly innovative therapeutic products and technologies. He gained significant experience with cell-based therapeutics while at Valentis (formerly GeneMedicine; The Woodlands, TX) where he rose to Senior Director Preclinical Development and led multi-site, multidisciplinary product development teams advancing two new gene therapy products from animal proof-of-concept to human clinical testing.

During his time at Valentis, Ross also participated in developing five additional clinical stage products, and led the company’s manufacturing and quality control functions in manufacturing products for preclinical and clinical testing.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cell Medica Secures £17 Million Equity Investment
Investment to establish US operations and fund cell therapy development.
Monday, August 06, 2012
Scientific News
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!